Drug Trial Radar · NCT07179081
A Study of AL58805 in Patients With Advanced Tumors
Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 20, 2020
Primary completion
Jan 26, 2026
Study completion Jan 26, 2026
Sponsor
- Lead sponsor
- Advenchen Laboratories Nanjing Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase I clinical trial is a dose-escalation, multicenter study in patients with advanced solid tumors. It includes tolerance studies of sequential multiple oral doses of AL58805 and pharmacokinetic studies of single and multiple doses, analyzing the tolerance range of multiple doses, observing the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in solid tumor patients, and assessing the reversibility of toxicity and the relationship between toxicity and dose.
Conditions
- Advanced Tumors
Interventions
AL58805Drug
Oral,Multiple administrations, once or twice daily(20mg 、40mg QD; 20mg 、30mg、40mg、50mg、60mg BID;)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicityTime frame: From signing the ICF until 28 days after the first dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.